Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06534905 · ClinicalTrials.gov registry record · NA

E-cigarette Switching Older Adults

A NA study of Opioid Use Disorder and Tobacco Use, sponsored by University of Maryland, Baltimore.

Active
Registry status
NA
Development phase
36
Enrollment target
1
Study location

NCT06534905: Active NA study of Opioid Use Disorder and Tobacco Use, sponsored by University of Maryland, Baltimore.

NCT06534905 is a NA study of Opioid Use Disorder and Tobacco Use that is active but no longer recruiting, run by University of Maryland, Baltimore. The registered enrollment target is 36 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06534905, a NA study of Opioid Use Disorder and Tobacco Use, is active but no longer recruiting, sponsored by University of Maryland, Baltimore.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn if adults 50 years and older who currently smoke tobacco and are in treatment for opioid use disorder will switch to using e-cigarettes instead of continued smoking. Participants will not have a plan to quit smoking and will not be actively trying to quit smoking at the start of the trial. The main questions the study aims to answer are: * Are e-cigarettes a feasible and acceptable harm-reduction tool among older adults who currently smoke tobacco and don\'t have a plan to quit? * Will switching to e-cigarettes and reducing tobacco use be more likely among patients given access to e-cigarettes compared to individuals who are exposed to a standard brief intervention for smoking cessation (control)? * Does the accuracy of nicotine/tobacco knowledge change after participants are exposed to education on the harms of nicotine relative to no education? Participants will complete a baseline session (BL) and follow-up visits at weeks 2, 6, and 8, each lasting 30-90 minutes, for a total of approximately 3-4 hours of participation in the study. Each session will include computerized assessments of tobacco and other substance use, health status, mood, and functioning. Patients will be randomly assigned at baseline (if meeting eligibility criteria) to receive an e-cigarette product (name of product: NJOY Ace) or brief advice to quit smoking (in alignment with recommendations by the American Society of Addiction Medicine).

Primary Outcome

Measured by self-report in response to following question "Do you intend to stop smoking in the next month?"

Interventions

  • OTHER E-cigarette
  • BEHAVIORAL Control/Standard Advice

Study Locations (1)

Maryland

  • University of Maryland Addiction Treatment Center (UMATC) - Baltimore

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2024-11-25
Est. Completion 2026-07
Phase NA
University of Maryland, Baltimore

560 total trials

What the registry record for NCT06534905 still lists

NCT06534905 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which E-cigarette is the first listed.

NCT06534905 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT06534905 about?

NCT06534905 is a clinical study titled "E-cigarette Switching Older Adults". The goal of this clinical trial is to learn if adults 50 years and older who currently smoke tobacco and are in treatment for opioid use disorder will switch to using e-cigarettes instead of continued smoking. Participants will not have a plan to quit smoking and will not be actively trying to quit ...

What is the current status of trial NCT06534905?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 36 participants. The study started on 2024-11-25. Estimated completion is 2026-07.

What conditions does trial NCT06534905 study?

This clinical trial studies the following conditions: Opioid Use Disorder, Tobacco Use, Tobacco-Related Disorders.

What interventions are being tested in trial NCT06534905?

The interventions under investigation include: E-cigarette (OTHER), Control/Standard Advice (BEHAVIORAL).

Who is sponsoring clinical trial NCT06534905?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06534905 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06534905's enrollment target sits among peer trials

36 193rd of 257 higher than 63 of 257 other Opioid Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06534905, the US trial registry maintained by the National Library of Medicine. NCT06534905 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.